



EI · CML

EUROPEAN INVESTIGATORS ON CML

22nd Meeting of the European Investigators on CML

Saint-Petersburg, May, 15-18, 2014

Scientific program



Meeting chairs:

Rudiger Hehlmann (Germany)

Andrey Zaritskey (Russia)

Thursday, May 15.

Individual arriving.

20:00 Welcome dinner.

Friday, May 16.

09:00-10:30

Andrey Zaritskey, Rudiger Hehlmann Welcome. Introduction.

Rudiger Hehlmann CML-Study IV: Efficacy and safety of imatinib over 10 years

Markus Pfirrmann Overall survival and prognosis in patients with first line imatinib treatment considering death due to CML as the only event.

Stephen O'Brien The SPIRIT 2 trial and the progress of SPIRIT 3 in the UK

Josef Thaler TKI combinations, including INF.

Themistoklis Kalmantis The Rising Costs of New Drugs for CML and other Malignant and Non-Malignant Chronic Disorders may affect Treatment Decisions not only in Countries under Economic Crisis but also in others with Stronger Economies.

Vasily Shuvaev Pharmacoeconomic modelling of CML treatment

10:30-11:00 Coffee break

11:00-12:30

Susanne Saussele Stopping trials.

Josef Thaler MRD- stop TKI.

Philippe Rousselot BCR-ABL fluctuations after treatment discontinuation.

Ekaterina Chelysheva Management of CML patients without treatment.

Eilsabetta Abruzzese Pregnancy/conception and TKI

Khamida Kazakbaeva CML treatment in Uzbekistan and management of pregnancy in CML patients.

12:30 - 13:30 Lunch.

13:30-15:00

Boris Afanasiev Role of SCT in CML treatment

Elena Morozova Effect of prior therapy with nilotinib or dasatinib on the outcome after alloSCT for patients with CML

Manuel Abecasis Chronic myeloid leukemia: lessons learned from a case report

Arnon Nagler Combination of Imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivo.

Alexander Lavrov Looking for new prognostic factors using whole exome sequencing of primary CML patients.

Pavel Butylin Mesenchymal-hematopoietic cell interactions in CML

15:00-15:30 Coffee break

16:00-17:30 Outside meeting

18:00 Dinner.

19:15-23:00 Outside meeting

Saturday, May 17.

08:45-12:00 Outside meeting

12:00-12:45 Lunch

13:00-16:00 Outside meeting

16:00-16:30 Coffee break

16:30-18:30

Josef Thaler Side effects of TKI, esp. PAD

Susanne Saussele Assessment of comorbidities - influence on outcome.

Elza Lomaia Prospective study to evaluate the mechanisms of vascular complications during therapy with TKIs in CP CML patients

Michael Dubina Peptide approach for targeted siRNA delivery against BCR-ABL transcripts in vitro

Philippe Rousselot Tyrosine kinase inhibitors optimization based on pharmacokinetics

Irina Martynkevich Timely switching of TKIs depends on BCR-ABL level at 3 months

Valeria Shlyakhto Individual early dynamics of BCR-ABL transcripts as an optimized predictor of survival in CML

Andrey Zaritskey Closing remarks.

19:00 Dinner.

22:30 - 03:00 Outside meeting

Sponsors:



Bristol-Myers Squibb

